epinephrine (OX640)
/ Orexo
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 16, 2025
Pharmacokinetics and pharmacodynamics of nasal epinephrine powder under normal and allergic rhinitis conditions
(EAACI 2025)
- "Notably, mean hemodynamic effects from the IM injection were qualitatively different from nasal administrations, with insignificant effects on heart rate and systolic blood pressure and negative effects on diastolic blood pressure. Conclusion The OX640 epinephrine nasal powder rapidly produced plasma levels comparable to or exceeding the reference IM injection, accompanied with relevant hemodynamic effects, supporting the potential utility of OX640 for treatment of anaphylaxis."
Late-breaking abstract • PK/PD data • Allergic Rhinitis • Immunology • Inflammation
January 10, 2025
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
(PRNewswire)
- P1 | N=30 | "Orexo AB...today announces positive topline results from the clinical study OX640-002...Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. Absorption under allergic rhinitis conditions was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with significant airway symptoms. OX640 formulations typically produced more pronounced increases in blood pressure and heart rate than the intramuscular injection, which are key effects for treatment of anaphylaxis. Systemic safety was in line with the known pharmacology of epinephrine and local effects were transient and tolerated. There were no severe or serious adverse events."
P1 data • Allergic Rhinitis
1 to 2
Of
2
Go to page
1